Osteoporosis historical perspective: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 48: | Line 48: | ||
|} | |} | ||
* 4000 years old Egyptian [[Mummy baby|mummies]] showed the revealing sign of [[osteoporosis]] called "Dowager's hump"; | * 4000 years old Egyptian [[Mummy baby|mummies]] showed the revealing sign of [[osteoporosis]] called "Dowager's hump"; [[osteoporosis]], [[Bone]] with holes, is seen for the first time. | ||
* In 1800's, [[Osteoporosis]] was first discovered by John Hunter, British [[surgeon]]. He found that [[bones]] in [[human body]] are turning over, continuously; when some old or dysfunctioned [[bone]] tissue become eroded and eliminated, the new fully functioned one being substituted. Nowadays, the process is called remodeling, the most important issue in [[osteoporosis]] [[pathophysiology]]. | * In 1800's, [[Osteoporosis]] was first discovered by John Hunter, British [[surgeon]]. He found that [[bones]] in [[human body]] are turning over, continuously; when some old or dysfunctioned [[bone]] tissue become eroded and eliminated, the new fully functioned one being substituted. Nowadays, the process is called remodeling, the most important issue in [[osteoporosis]] [[pathophysiology]]. | ||
* In 1830's, Jean Lobstein, a French [[pathologist]], found that there are normal holes in every [[bones]]; but some people's [[bones]] from specific age and [[diseases]] may have larger holes than normal ones. He eventually named theses kinds of [[bones]] as ''[[porous]]''; thus the [[disease]] became called ''[[osteoporosis]]''.<ref name="urlHistory of Osteoporosis">{{cite web |url=http://reliawire.com/history-osteoporosis/ |title=History of Osteoporosis |format= |work= |accessdate=}}</ref> | * In 1830's, Jean Lobstein, a French [[pathologist]], found that there are normal holes in every [[bones]]; but some people's [[bones]] from specific age and [[diseases]] may have larger holes than normal ones. He eventually named theses kinds of [[bones]] as ''[[porous]]''; thus the [[disease]] became called ''[[osteoporosis]]''. Many developments have been made in the treatment and [[prevention]] of [[osteoporosis]] over the years; however, [[osteoporosis]] remains a significant challenge within the field of medicine.<ref name="urlHistory of Osteoporosis">{{cite web |url=http://reliawire.com/history-osteoporosis/ |title=History of Osteoporosis |format= |work= |accessdate=}}</ref> | ||
* In 1830's, the link between age-related reductions in [[bone]] [[density]] and [[Bone fracture|fracture]] risk determined by Astley Cooper. The term "[[osteoporosis]]", recognition of its [[pathological]] appearance is generally attributed to the French [[pathologist]], Lobstein.<ref>Lobstein JGCFM. ''Lehrbuch der pathologischen Anatomie.'' Stuttgart: Bd II, 1835.</ref> | * In 1830's, the link between age-related reductions in [[bone]] [[density]] and [[Bone fracture|fracture]] risk determined by Astley Cooper. The term "[[osteoporosis]]", recognition of its [[pathological]] appearance is generally attributed to the French [[pathologist]], Lobstein.<ref>Lobstein JGCFM. ''Lehrbuch der pathologischen Anatomie.'' Stuttgart: Bd II, 1835.</ref> | ||
* In 1940's, the American [[endocrinologist]], Fuller Albright from [[Massachusetts General Hospital]], linked [[osteoporosis]] with the [[postmenopausal]] state. Thus, he started to treat [[menopausal]] women with [[estrogen]] in order to prevent further [[bone]] loss.<ref>{{cite journal | author=Albright F, Bloomberg E, Smith PH|year=1940 |month= |title= Postmenopausal osteoporosis |journal=Trans. Assoc. Am. Physicians. |volume=55 |pages=298-305}}</ref> | * In 1940's, the American [[endocrinologist]], Fuller Albright from [[Massachusetts General Hospital]], linked [[osteoporosis]] with the [[postmenopausal]] state. Thus, he started to treat [[menopausal]] women with [[estrogen]] in order to prevent further [[bone]] loss.<ref>{{cite journal | author=Albright F, Bloomberg E, Smith PH|year=1940 |month= |title= Postmenopausal osteoporosis |journal=Trans. Assoc. Am. Physicians. |volume=55 |pages=298-305}}</ref> | ||
| Line 57: | Line 57: | ||
* In 1984, the [[National Institute of Health|National Institute of Health (NIH)]] publicized this [[disease]], and brought attention to [[osteoporosis]] as a significant threat to [[health]]; with the emphasis that [[bone loss]] could be reduced by [[estrogen]] therapy, [[calcium]] supplementation, good [[nutrition]], and [[Physical exercise|exercise]].<ref name="urlThe National Institutes of Health (NIH) Consensus Development Program: Osteoporosis">{{cite web |url=https://consensus.nih.gov/1984/1984Osteoporosis043html.htm |title=The National Institutes of Health (NIH) Consensus Development Program: Osteoporosis |format= |work= |accessdate=}}</ref> | * In 1984, the [[National Institute of Health|National Institute of Health (NIH)]] publicized this [[disease]], and brought attention to [[osteoporosis]] as a significant threat to [[health]]; with the emphasis that [[bone loss]] could be reduced by [[estrogen]] therapy, [[calcium]] supplementation, good [[nutrition]], and [[Physical exercise|exercise]].<ref name="urlThe National Institutes of Health (NIH) Consensus Development Program: Osteoporosis">{{cite web |url=https://consensus.nih.gov/1984/1984Osteoporosis043html.htm |title=The National Institutes of Health (NIH) Consensus Development Program: Osteoporosis |format= |work= |accessdate=}}</ref> | ||
* In 1980's and 1990's researchers discovered the specific [[cytokines]] which influence the activity of [[osteoclasts]], the components that cause [[bone]] breakdown.<ref name="pmid26491648">{{cite journal| author=Pagliari D, Ciro Tamburrelli F, Zirio G, Newton EE, Cianci R| title=The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis. | journal=Anal Cell Pathol (Amst) | year= 2015 | volume= 2015 | issue= | pages= 434389 | pmid=26491648 | doi=10.1155/2015/434389 | pmc=4605147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26491648 }} </ref> | * In 1980's and 1990's researchers discovered the specific [[cytokines]] which influence the activity of [[osteoclasts]], the components that cause [[bone]] breakdown.<ref name="pmid26491648">{{cite journal| author=Pagliari D, Ciro Tamburrelli F, Zirio G, Newton EE, Cianci R| title=The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis. | journal=Anal Cell Pathol (Amst) | year= 2015 | volume= 2015 | issue= | pages= 434389 | pmid=26491648 | doi=10.1155/2015/434389 | pmc=4605147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26491648 }} </ref> | ||
* In 1994, [[World Health Organization|World Health Organization (WHO)]] first used T- | * In 1994, [[World Health Organization|World Health Organization (WHO)]] first used T-score as a measure for classification and definition of various amounts of [[Bone mineral density|bone mineral density (BMD)]]. The T-score was determined as the [[standard deviation]] of the [[Bone mineral density|BMD]] for a single patient in contrast with a standard population sample. The population sample is always a young, healthy person, matched for sex and [[race]].<ref name="pmid7941614">{{cite journal |vauthors= |title=Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group |journal=World Health Organ Tech Rep Ser |volume=843 |issue= |pages=1–129 |year=1994 |pmid=7941614 |doi= |url=}}</ref> | ||
* In 1998, [[Selective estrogen receptor modulator|Selective estrogen receptor modulators (SERMs)]], such as [[raloxifene]], entered the market. They also have been found to treat [[breast tumors]] and to stimulate the [[growth]] of [[uterine]] cells.<ref name="raloxifen">{{cite book | last = Macor| first = John| title = Annual reports in medicinal chemistry | publisher = Elsevier/Academic Press | location = London, UK | year = 2008 | isbn = 9780123743442 }}</ref> | * In 1998, [[Selective estrogen receptor modulator|Selective estrogen receptor modulators (SERMs)]], such as [[raloxifene]], entered the market. They also have been found to treat [[breast tumors]] and to stimulate the [[growth]] of [[uterine]] cells.<ref name="raloxifen">{{cite book | last = Macor| first = John| title = Annual reports in medicinal chemistry | publisher = Elsevier/Academic Press | location = London, UK | year = 2008 | isbn = 9780123743442 }}</ref> | ||
Revision as of 15:17, 17 August 2017
|
Osteoporosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Osteoporosis historical perspective On the Web |
|
American Roentgen Ray Society Images of Osteoporosis historical perspective |
|
Risk calculators and risk factors for Osteoporosis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Osteoporosis was first discovered by John Hunter, British surgeon, in 1800's. He found that bones in human body are turning over, continuously; when some old or dysfunctioned bone tissue become eroded and eliminated, the new fully functioned one being substituted. Nowadays, the process is called remodeling, the most important issue in osteoporosis pathophysiology. Jean Lobstein, a French pathologist of 1830's, found that there are normal holes in every bones; but some people's bones from specific age and diseases may have larger holes than normal ones. He eventually named theses kinds of bones as porous; thus the disease became called osteoporosis.
Historical perspective
Here is the diagram that shows the historical perspective of osteoporosis during decades, at a glance.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- 4000 years old Egyptian mummies showed the revealing sign of osteoporosis called "Dowager's hump"; osteoporosis, Bone with holes, is seen for the first time.
- In 1800's, Osteoporosis was first discovered by John Hunter, British surgeon. He found that bones in human body are turning over, continuously; when some old or dysfunctioned bone tissue become eroded and eliminated, the new fully functioned one being substituted. Nowadays, the process is called remodeling, the most important issue in osteoporosis pathophysiology.
- In 1830's, Jean Lobstein, a French pathologist, found that there are normal holes in every bones; but some people's bones from specific age and diseases may have larger holes than normal ones. He eventually named theses kinds of bones as porous; thus the disease became called osteoporosis. Many developments have been made in the treatment and prevention of osteoporosis over the years; however, osteoporosis remains a significant challenge within the field of medicine.[1]
- In 1830's, the link between age-related reductions in bone density and fracture risk determined by Astley Cooper. The term "osteoporosis", recognition of its pathological appearance is generally attributed to the French pathologist, Lobstein.[2]
- In 1940's, the American endocrinologist, Fuller Albright from Massachusetts General Hospital, linked osteoporosis with the postmenopausal state. Thus, he started to treat menopausal women with estrogen in order to prevent further bone loss.[3]
- In 1960's, researchers developed more sensitive methods to detect early bone loss; such as bone densitometers.
- In 1960's, bisphosphonates which inhibit bone resorption, and revolutionized the treatment of osteoporosis were discovered by Herbert Fleisch.[4]
- In 1984, the National Institute of Health (NIH) publicized this disease, and brought attention to osteoporosis as a significant threat to health; with the emphasis that bone loss could be reduced by estrogen therapy, calcium supplementation, good nutrition, and exercise.[5]
- In 1980's and 1990's researchers discovered the specific cytokines which influence the activity of osteoclasts, the components that cause bone breakdown.[6]
- In 1994, World Health Organization (WHO) first used T-score as a measure for classification and definition of various amounts of bone mineral density (BMD). The T-score was determined as the standard deviation of the BMD for a single patient in contrast with a standard population sample. The population sample is always a young, healthy person, matched for sex and race.[7]
- In 1998, Selective estrogen receptor modulators (SERMs), such as raloxifene, entered the market. They also have been found to treat breast tumors and to stimulate the growth of uterine cells.[8]
References
- ↑ "History of Osteoporosis".
- ↑ Lobstein JGCFM. Lehrbuch der pathologischen Anatomie. Stuttgart: Bd II, 1835.
- ↑ Albright F, Bloomberg E, Smith PH (1940). "Postmenopausal osteoporosis". Trans. Assoc. Am. Physicians. 55: 298–305.
- ↑ Patlak M (2001). "Bone builders: the discoveries behind preventing and treating osteoporosis". FASEB J. 15 (10): 1677E–E. PMID 11481214.
- ↑ "The National Institutes of Health (NIH) Consensus Development Program: Osteoporosis".
- ↑ Pagliari D, Ciro Tamburrelli F, Zirio G, Newton EE, Cianci R (2015). "The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis". Anal Cell Pathol (Amst). 2015: 434389. doi:10.1155/2015/434389. PMC 4605147. PMID 26491648.
- ↑ "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group". World Health Organ Tech Rep Ser. 843: 1–129. 1994. PMID 7941614.
- ↑ Macor, John (2008). Annual reports in medicinal chemistry. London, UK: Elsevier/Academic Press. ISBN 9780123743442.